More Articles

BIO wants to delay biodissimilars as long as possible Biosimilars/News | Posted 31/08/2009

Biotech drugs are big revenue earners. Their sales growth rate may have slipped back into single figures last year, but according to IMS Health data they still accounted for more than 37% of the gr...

Obama wants to introduce US biosimilars pathway Biosimilars/News | Posted 31/08/2009

US President Barack Obama plans to fund part of his healthcare reform plans by backing an approval pathway for generic biologicals. As reported by Christopher Spillane in Scrip News, Mr Obama lobbi...

Watson to acquire Arrow to double generics business Generics/News | Posted 31/08/2009

Watson Pharmaceuticals announced it has entered into a definitive agreement to acquire privately held Arrow Group for US$1.75 billion (Euros 1.25 billion) in cash and stock. The combination of Wats...

Potential pitfalls in entering China's generics market Policies & Legislation | Posted 31/08/2009

China's fast-growing pharmaceuticals market is proving attractive to many foreign pharmaceutical firms, including those in the generics sector. Such companies need to be aware of potential pitfalls...

BIO: Patent gap for biologicals ignored by Federal Trade Commission report Policies & Legislation | Posted 31/08/2009

In the US, the outstanding issue surrounding the biosimilars debate remains the exclusivity period before competitors can come on the US market – and the US is no closer to a resolution following t...

Pfizer plans partnerships and acquisitions in generics Generics/News | Posted 31/08/2009

Pfizer, the world's biggest drugmaker, is seeking deals with generic pharmaceutical manufacturers to increase sales of medicines that have lost patent protection.

EGA report: Increase patient access to generic medicines Reports | Posted 05/08/2009

“EU governments need to ensure fast generic medicines uptake, as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient acc...

US Federal Trade Commission issues report on biosimilars Biosimilars/News | Posted 05/08/2009

The US Federal Trade Commission (FTC) released a report entitled Follow-on Biologic Drug Competition, which examines whether the price of biological drugs could be reduced by competition from so-ca...